Cooper Companies (The) (COO)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
$69.61-3.17%
Close 2026-07-08 · 1-day change
Reading COO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track COO free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-08
Reading COO? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track COO free→QuarterlyIQ Insights · COO
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $69.61. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $72 COO trades at 21× p/e, below its 30× p/e peer median. Our $82 fair value sits above the price. It's a high-confidence read. Analysts target $61–$86. Not investment advice.
$61.00 – $86.00 (median $85.00) · 5 analysts · as of 2026-06-05
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $2.00/sh owner earnings.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $85.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $76.72 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $73.48 | — | — | Hist. CAGR | high |
| graham number | 12M | $56.85 | — | — | TTM | high |
| Mgmt guidance | 12M | $137.32 | 29.7 | 4.62 | Mgmt | high |
| Peer EV/EBITDA | 12M | $54.32 | 14.0 | 4.72 | TTM | high |
| Peer P/FCF | 12M | $80.67 | 27.6 | 2.92 | TTM | high |
| Peer P/E | 12M | $101.06 | 29.7 | 3.40 | TTM | high |
| Peer P/S | 12M | $57.10 | 2.6 | 21.70 | TTM | high |
| PEG | 12M | $131.85 | 38.8 | 3.40 | TTM | high |
| residual income | 12M | $41.12 | — | — | TTM | high |
| Own P/E history | 12M | $76.62 | 22.5 | 3.40 | TTM | high |
| triangulated | 12M | $101.98 | 29.7 | 3.43 | Triangulated | high |
| Mgmt guidance | 3Y | $330.47 | 29.7 | 11.12 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $118.61 | 27.6 | 4.29 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $152.96 | 29.7 | 5.15 | Analyst | medium |
| Peer P/S | 3Y | $62.75 | 2.6 | 23.85 | guidance | medium |
| PEG | 3Y | $199.58 | 38.8 | 5.15 | Analyst | medium |
| Own P/E history | 3Y | $115.98 | 22.5 | 5.15 | Analyst | medium |
| Mgmt guidance | 5Y | $593.49 | 29.7 | 19.97 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $153.38 | 27.6 | 5.55 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $158.21 | 29.7 | 5.32 | Analyst | high |
| Peer P/S | 5Y | $64.91 | 2.6 | 24.66 | guidance | high |
| PEG | 5Y | $206.43 | 38.8 | 5.32 | Analyst | high |
| Own P/E history | 5Y | $119.96 | 22.5 | 5.32 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.